Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Killingberg KT, Halvorsen TO, Fløtten Ø, Brustugun OT, Langer SW, Nyman J, Hornslien K, Madebo T, Schytte T, Risum S, Tsakonas G, Engleson J, Grønberg BH. Killingberg KT, et al. Among authors: brustugun ot. Lung Cancer. 2022 Apr;166:49-57. doi: 10.1016/j.lungcan.2022.02.002. Epub 2022 Feb 8. Lung Cancer. 2022. PMID: 35183991 Free article. Clinical Trial.
[Mutation testing for non-small-cell lung cancer].
Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L. Brustugun OT, et al. Tidsskr Nor Laegeforen. 2012 Apr 30;132(8):952-5. doi: 10.4045/tidsskr.11.1017. Tidsskr Nor Laegeforen. 2012. PMID: 22562326 Free article. Norwegian.
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Grønberg BH, Lund-Iversen M, Strøm EH, Brustugun OT, Scott H. Grønberg BH, et al. Among authors: brustugun ot. J Thorac Oncol. 2013 Oct;8(10):1255-64. doi: 10.1097/JTO.0b013e3182a406a3. J Thorac Oncol. 2013. PMID: 24457236 Free article. Clinical Trial.
BRAF-mutations in non-small cell lung cancer.
Brustugun OT, Khattak AM, Trømborg AK, Beigi M, Beiske K, Lund-Iversen M, Helland Å. Brustugun OT, et al. Lung Cancer. 2014 Apr;84(1):36-8. doi: 10.1016/j.lungcan.2014.01.023. Epub 2014 Feb 3. Lung Cancer. 2014. PMID: 24552757
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S; Norwegian Lung Cancer Study Group. Grønberg BH, et al. Among authors: brustugun ot. Acta Oncol. 2016 May;55(5):591-7. doi: 10.3109/0284186X.2015.1092584. Epub 2015 Oct 23. Acta Oncol. 2016. PMID: 26494411 Clinical Trial.
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.
Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM. Donnem T, et al. Among authors: brustugun ot. Ann Oncol. 2016 Feb;27(2):225-32. doi: 10.1093/annonc/mdv560. Epub 2015 Nov 16. Ann Oncol. 2016. PMID: 26578726 Free article. Review.
147 results